All In Biotech

Drug Trial Radar · NCT03605680

A Trial Evaluating the Efficacy, Safety, & Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder

A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group Trial Evaluating the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder

Last checked: Nov 20, 2026Latest source record: Mar 15, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 604 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

604

Actual

Start

Jan 16, 2019

Primary completion

Apr 11, 2020

Study completion Apr 11, 2020

Sponsor

Sponsor type
Industry
First posted
Jul 30, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates the efficacy, safety, and tolerability of centanafadine sustained-release tablets in adults with attention-deficit/hyperactivity disorder (ADHD). Participants will either receive a twice-daily dose of centanafadine sustained-release tablets, or twice-daily placebo.

Conditions

  • Attention Deficit Disorder
  • Attention Deficit Hyperactivity Disorder

Interventions

  • Centanafadine SRDrug

    100 mg, BID, oral tablets

  • PlaceboOther

    BID, oral tablet.

  • Centanafadine SRDrug

    200 mg, BID, oral tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in ADHD Investigator Symptom Rating Scale (AISRS)Time frame: Baseline and Day 42

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • For additional information regarding sites, contact 844-687-8522

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.